Thermo Fisher Scientific has completed the acquisition of PeproTech. Credit: Raysonho / commons.wikimedia.org.

Thermo Fisher Scientific has completed the acquisition of PeproTech for a total cash consideration of approximately $1.85bn.

Based in the US, PeproTech develops bioscience reagents known as recombinant proteins, which include growth factors and cytokines.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

These reagents are used in the development and manufacturing of cell and gene therapies as well as in wide cell culture applications, which are mainly models related to cellular research.

Thermo Fisher stated that the recombinant proteins portfolio of PeproTech complements its cell culture media products.

Additionally, Thermo Fisher will be able to offer significant benefits to customers through an integrated offering.

It also noted that the transaction increases its capabilities to serve the cell and gene therapy market.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Thermo Fisher Scientific chairman, president and CEO Marc Casper said: “PeproTech will be an excellent strategic fit within our biosciences business and will allow us to even better serve our pharma and biotech customers by adding new capabilities to our existing offering.

“In combination with our proprietary bioprocessing and cell culture technologies, this complementary transaction positions us to partner with our customers to drive the evolution of the fast-growing market for cell and gene therapies.

“By leveraging our commercial reach, we will be able to efficiently grow the PeproTech business and generate attractive financial results all while furthering our mission to enable our customers to make the world healthier, cleaner and safer.”

Following the acquisition, PeproTech will be integrated into the Life Sciences Solutions Segment to become part of Thermo Fisher’s biosciences business.

Last November, Thermo Fisher confirmed that its polymerase chain reaction (PCR) TaqPath Covid-19 Combo Kit and TaqPath Covid-19 CE-IVD RT-PCR Kit can accurately detect the new emerging Covid-19 variant, Omicron (B.1.1.529).

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact